What lipid modification therapy should I offer for secondary prevention if a statin is not suitable?
• Consider offering a fibrate, modified-release nicotinic acid or a bile acid sequestrant. • Evidence supporting the use of these drugs for secondary prevention is poor compared to statins. • The decision to select a particular lipid-modifying drug should take into account patient preference and tolerability, comorbidities, multiple drug therapy, and the benefits and risks of treatment.
Related Questions
- Are Savings from Secondary Prevention (Such as Antihypertensive Therapy after Stroke or after Carotid Endarterectomy) Quantifiable?
- What lipid modification therapy should I offer for secondary prevention if a statin is not suitable?
- Which Lipid Parameters Should Be Measured in Primary and Secondary Prevention of Stroke?
